IL17A and juvenile idiopathic arthritis: Given the pathogenic role of interleukin-17 and, in particular, member IL-17A in these forms of JIA (as demonstrated in the studies described above), as well as the limited effectiveness of currently available therapies (including JPsA [117] and ERA [118,119,120,121,122]), it was hypothesized that secukinumab could be successfully used in the treatment of these two forms of JIA.